Delay Analysis Methods (Dams) in Construction Contracts in India

Kabre, Chitrarekha; Kumar, Parvesh

doi:10.14529/build190406

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, delays are frequent in projects (Flyvbjerg 2014), particularly large ones (Park 2021), and they have a detrimental impact on their performance (Eizakshiri et al 2015), both directly (Siemiatycki 2018) and indirectly (Braimah 2013). Given the relevance, and frequency of delays in projects, appropriate methods have been developed, in particular the so-called Delay Analysis Techniques (DATs), sometimes denoted by various alternative terms (Kabre and Kumar 2019). DATs comprise an array of quantitative methods to assess the impact of delays on projects and stakeholders (Braimah 2013;Yang and Kao 2009).…”

Section: Introductionmentioning

confidence: 99%

The Evolution of Forensic Delay Analysis: A Literature Review Investigating Changes and Progress in Project Management Approaches to Delay Measurement

Grzeszczyk,

Sainati,

Unterhitzenberger

2024

J. Leg. Aff. Dispute Resolut. Eng. Constr.

View full text Add to dashboard Cite

This literature review explores the topic of Forensic Delay Analysis (FDA), highlighting recent advances and key themes currently attracting research interest within the area. Project delays in every context can have significant financial and non-financial impacts, so it is crucial to accurately identify and assess their influence. Our analysis shows that despite the initial conceptualisation of FDA methods and tools, the field remains complex and laborious, and its credibility is often contested due to . The findings suggest that FDA has received insufficient research attention compared to other project management domains and has made limited progress since its inception. Furthermore, there is no consistent approach to measuring delays, despite their prevalence, severity and global persistence. Although a wide range of publications acknowledge the continuing interest in FDA, most confirm its limited applicability and inadequate standardisation. The literature also highlights lack of progress in this area of knowledge predominantly due to lack of innovative perspectives, tools and understanding. In order to improve the credibility and reliability of FDA and DATs, it is therefore essential to embrace and promote alternative and innovative knowledge. This paper will appeal to a wide audience, including academics and practitioners, who wish to explore the limitations of FDA and the knowledge gaps identified in the existing literature.

show abstract